Jan Adolfsson
Overview
Explore the profile of Jan Adolfsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
3721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin R, Turner E, Young G, Metcalfe C, Walsh E, Athene Lane J, et al.
JAMA
. 2024 Apr;
331(17):1460-1470.
PMID: 38581198
Importance: The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary...
2.
Ludvigsson J, Adolfsson J, Hoistad M, Rydelius P, Kristrom B, Landen M
Acta Paediatr
. 2023 Apr;
112(11):2279-2292.
PMID: 37069492
Aim: The aim of this systematic review was to assess the effects on psychosocial and mental health, cognition, body composition, and metabolic markers of hormone treatment in children with gender...
3.
Muller L, Adolfsson J, Forsberg L, Bring J, Dahlgren J, Domeij H, et al.
Eur Radiol
. 2023 Apr;
33(8):5258-5268.
PMID: 37042982
Introduction: Radiographs of the hand and teeth are frequently used for medical age assessment, as skeletal and dental maturation correlates with chronological age. These methods have been criticized for their...
4.
George G, Garmo H, Adolfsson J, Elf K, Gedeborg R, Holmberg L, et al.
J Oncol
. 2023 Feb;
2023:9527920.
PMID: 36844872
An inverse association between use of antiepileptic drugs (AEDs) and prostate cancer (PCa) has been suggested, putatively due to the histone deacetylases inhibitory (HDACi) properties of the AEDs. In a...
5.
Lin E, Garmo H, Hagstrom E, Van Hemelrijck M, Adolfsson J, Stattin P, et al.
Br J Cancer
. 2022 Dec;
128(5):814-824.
PMID: 36522475
Background: Gonadotropin-releasing hormone agonists (GnRH) used in prostate cancer (PCa) are associated with atherogenic dyslipidaemia. It can be assumed that GnRH need to be used with greater caution in men...
6.
Ventimiglia E, Bill-Axelson A, Adolfsson J, Aly M, Eklund M, Westerberg M, et al.
Eur Urol Open Sci
. 2022 Oct;
44:46-51.
PMID: 36185582
Background: Little is known about disease trajectories for men with castration-resistant prostate cancer (CRPC). Objective: To create a state transition model that estimates time spent in the CRPC state and...
7.
Lin E, Garmo H, Van Hemelrijck M, Zethelius B, Stattin P, Hagstrom E, et al.
JAMA Netw Open
. 2022 Aug;
5(8):e2225600.
PMID: 35939302
Importance: Men with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Meanwhile, gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer (PCa) are associated with increased risk of...
8.
9.
Bonde T, Westerberg M, Aly M, Eklund M, Adolfsson J, Bill-Axelson A, et al.
Scand J Urol
. 2022 May;
56(3):169-175.
PMID: 35548951
To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death by use of clinical variables at Pca diagnosis and PSA levels after start of gonadotropin-releasing hormone agonists (GnRH) in...
10.
Khoshkar Y, Westerberg M, Adolfsson J, Bill-Axelson A, Olsson H, Eklund M, et al.
BJUI Compass
. 2022 Apr;
3(2):173-183.
PMID: 35474724
Objectives: The objective of this study is to find clinical variables that predict the prognosis for men with castration-resistant prostate cancer (CRPC) in a Swedish real-life CRPC cohort, including a...